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Whole organ transplantation practices have brought this form of surgi-
cal treatment to a high level of efficiency and success, contrary to the 
pessimistic predictions at the outset of most immunologists. Historically, 
an allograft was envisioned as defenseless and vulnerable to immu-
nologic attack in proportion to its histocompatibility disparity with that of 
the recipient. This dogma defined transplantation in terms of a unidirec-
tional immune reaction both for bone marrow and organs (a one-way 
paradigm) (Figure I). 
The one-way paradigm was unchallenged for more than 3 decades 
until in 1992. we discovered the presence of ubiquitous low level donor 
leukocyte chimerism in our human organ recipients as long as 30 years 
post-transplantation (1,2). We postulated from these findings (and sub-
sequently obtained much confirmatory evidence [3-5]) that the interac-
tion of 2 coexisting donor and recipient leukocyte populations, each to 
the other. was the generic mechanism of successful tolerance after bone 
marrow transplantation as well as the "acceptance" of organ allografts 
(Figure 2). 
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The phenomenology of microchimerism has been widely verified in 
experimental models. The mutual cancelling effect of the coexisting cell 
populations explains: the blurring of an MHC matching effect on out-
come of organ transplantation, the ability to transplant histoincompatible 
liver, intestine, and bone marrow to the non-cytoablated recipient without 
causing GVHD, and the ability to stop immunosuppression in ruany or-
gan recipients (1,2,6). Most importantly, this concept provides a fresh 
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context to exploit basic immunologic information in xenotransplantation 
and other initiativeso 
This "2-way (bidirectional) paradigm" has been under intense exami-
nation because it has mandated reexamination of transplantation immu-
nology at every level. First, the 2-way paradigm established the long 
sought linkage between the whole organ transplant practices that were 
evolved empirically and the neonatal acquired immunologic tolerance 
2nd World Concress I 
I.HoPoBoAol 
Ir:crr.at:or.a; 
eecaio·mancrea~o·Blfgary 
ASSOCiation 
Bologna. Italy 
2-6 June 1996 
7 
2nd World Congress 
I.H.P.B.A. 
Intemabonal 
Hepalo·Pancrealo·B,ila,'Y 
ASSOClaDon 
Bologna. Italy 
2·6 June 1996 
8 
originally described more than 40 years ago by Billingham. Brent. and 
Medawar (7,8). The discoveries of spontaneous chimerism gave startling 
insight into what was actually being accomplished with whole organ 
transplantation, and this will be reviewed in a historic context. 
More importantly. these discoveries have illuminated the future (9). 
The mechanisms leading to chimerism and govern allograft acceptance 
also ultimately determine the outcome after xenotransplantatioll. Al-
though it will be difficult to first breech the humoral balTier, manipulat-
ing the individual limbs of the two-way reaction (host vs graft and graft 
vs host) is expected to be the key to the ultimate successful use of animal 
organs in humans. 
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